Antiandrogen therapy in hidradenitis suppurativa: finasteride for females. Academic Article uri icon

Overview

abstract

  • BACKGROUND: Given its widely accepted efficacy, androgen blockade therapy for hidradenitis suppurativa (HS) has become a standard of care. Although much less frequently used than spironolactone, a small number of HS studies have reported finasteride as an alternative treatment for women. In this study, we describe the response to and perception of finasteride therapy in a diverse cohort of women with HS. AIM: To describe finasteride therapy in a diverse cohort of female patients with HS. METHODS: We conducted an institutional review board-approved retrospective chart review and telephone survey of 20 female patients aged ≥ 18 years with a diagnosis of HS. Finasteride was prescribed by a single provider at a specialized HS centre. RESULTS: The mean age of the patients was 34.3 ± 13.5 years. Finasteride was initiated predominantly because of one or more contraindications or poor responsiveness to spironolactone. Most patients interviewed (90%; n = 18) were willing to take finasteride again or continue with therapy if indicated. Of the 20 patients, 10 (50%) reported overall satisfaction with finasteride, while 7 (35%) were neutral and 3 (15%) were dissatisfied. No patient reported worsening disease activity while on finasteride and only one (5%) reported decreased quality of life. When asked about adverse effects of finasteride, 80% (n = 16) reported none, while 20% (n = 4) experienced ≥ 1 of the following: headache, nausea, menstrual irregularities, breast tenderness or reduced libido/sexual function. CONCLUSIONS: Our study suggests that androgen blockade therapy with finasteride is a safe and effective alternative for female patients with HS who have contraindication(s) or intolerance to spironolactone.

publication date

  • August 31, 2021

Research

keywords

  • Androgen Antagonists
  • Finasteride
  • Hidradenitis Suppurativa

Identity

Scopus Document Identifier

  • 85113962047

Digital Object Identifier (DOI)

  • 10.1111/ced.14847

PubMed ID

  • 34260109

Additional Document Info

volume

  • 47

issue

  • 1